1-甲基-6-硝基-1H-吲哚 | 99459-48-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-甲基-6-硝基-1H-吲哚
• 英文名称: 1-methyl-6-nitro-indole
• 英文别名: 1-methyl-6-nitro-1H-indole；N-methyl-6-nitroindole；6-nitro-1-methylindole；1-methyl-6-nitroindole
• CAS: 99459-48-0
• 化学式: C₉H₈N₂O₂
• 分子量: 176.175
• InChiKey: AYGFFYXMDIOSFO-UHFFFAOYSA-N

物化性质

• 熔点：
  76.5-78.5 °C(Solv: ligroine (8032-32-4))
• 沸点：
  140-160 °C(Press: 0.1 Torr)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  50.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Methyl-6-nitroindole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Methyl-6-nitroindole
CAS number: 99459-48-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8N2O2
Molecular weight: 176.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-6-硝基-1H-吲哚 在 sodium hydroxide 、 氯化亚砜 、 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 115.25h， 生成 methyl (1-methyl-6-nitro-7-indolyl)acetate
  参考文献：
  名称：

  Synthesis, Biological Activity, and Molecular Modeling Studies of Selective 5-HT_2C/2B Receptor Antagonists

  摘要：

  The synthesis and biological activity are reported for a series of analogues of the previously published indole urea 2 (SB-206553), designed to probe the 5-HT2C receptor binding site. Small molecule modeling studies have been used to define a region in space which is allowed at the 5-HT2C receptor but disallowed at the 5-HT2A receptor. In a complementary approach, docking of 2 into our model of the 5-HT2C receptor has allowed us to propose a novel primary binding interaction for this series of diaryl ureas, involving a potential double hydrogen-bonding interaction between the urea carbonyl oxygen of the ligand and two serine residues in the receptor. The difference of two valine residues in the 5-HT2C receptor for leucine residues in the 5-HT2A receptor is believed to account for the observed 5-HT2C/5-HT2A selectivity with 2.

  DOI：

  10.1021/jm960571v
• 作为产物：
  描述：

  1-甲基吲哚啉 在 硫酸 、 硝酸 、 四氯苯醌 、 xylene 作用下， 生成 1-甲基-6-硝基-1H-吲哚
  参考文献：
  名称：

  Terent'ew; Preobrashenskaja, Doklady Akademii Nauk SSSR, 1958, vol. 118, p. 302,303

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] SULPHONAMIDE DERIVATIVES<br/>[FR] DERIVES SULFONAMIDES
  申请人：BIOTIE THERAPIES CORP

  公开号：WO2005090298A1

  公开（公告）日：2005-09-29

  The invention relates to sulphonamide derivatives of formula (I), where RC is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or RC forms together with the phenyl ring to which it is attached a benzodioxolyl group, or RC is -NR1R2, RA is a group having the formula (A), (B) or (C) RB is hydrogen or alkyl. The invention also relates to the use of derivatives of formula (I) as inhibitors for collagen receptor integrins and a process for preparing sulphonamides of formula (I).

  这项发明涉及式(I)的磺胺衍生物，其中RC是可选择取代的含有一个或多个N原子的4-6元杂环环，或者RC与其连接的苯环一起形成苯二氧杂环基团，或者RC是-NR1R2，RA是具有式(A)、(B)或(C)的基团，RB是氢或烷基。该发明还涉及将式(I)的衍生物用作胶原受体整合素的抑制剂以及制备式(I)的磺胺衍生物的方法。
• Sulphonamide Derivatives
  申请人：Smith David

  公开号：US20080255169A1

  公开（公告）日：2008-10-16

  The invention relates to sulphonamide derivatives of formula (I), where R C is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or R C forms together with the phenyl ring to which it is attached a benzodioxolyl group, or R C is —NR 1 R 2 , R A is a group having the formula R B is hydrogen or alkyl. The invention also relates to the use of derivatives of formula (I) as inhibitors for collagen receptor integrins and a process for preparing sulphonamides of formula (I).

  该发明涉及式(I)的磺胺基衍生物， 其中 R C 是可选取代的含有一个或多个N原子的4-6元杂环环，或 R C 与其连接的苯环一起形成苯二氧杂基团，或 R C 是-NR 1 R 2 ， R A 是具有式的基团 R B 是氢或烷基。 该发明还涉及将式(I)的衍生物用作胶原受体整合素的抑制剂以及制备式(I)的磺胺基的方法。
• Direct Palladium-Catalyzed C-2 and C-3 Arylation of Indoles:  A Mechanistic Rationale for Regioselectivity
  作者：Benjamin S. Lane、Meghann A. Brown、Dalibor Sames

  DOI：10.1021/ja043273t

  日期：2005.6.1

  We have recently developed palladium-catalyzed methods for direct arylation of indoles (and other azoles) wherein high C-2 selectivity was observed for both free (NH)-indole and (NR)-indole. To provide a rationale for the observed selectivity (“nonelectrophilic” regioselectivity), mechanistic studies were conducted, using the phenylation of 1-methylindole as a model system. The reaction order was determined

  我们最近开发了钯催化的吲哚（和其他唑类）直接芳基化方法，其中对游离 (NH)-吲哚和 (NR)-吲哚均观察到高 C-2 选择性。为了提供观察到的选择性（“非亲电”区域选择性）的基本原理，使用 1-甲基吲哚的苯基化作为模型系统进行了机理研究。确定碘苯（零级）、吲哚（一级）和催化剂（一级）的反应级数。这些动力学研究与哈米特图一起为亲电钯化途径提供了强有力的支持。此外，还测定了 C-2 和 C-3 位置的动力学同位素效应 (KIEH/D)。对于未发生取代的 C-3 位置（二级 KIE），发现了令人惊讶的大值 1.6，而在 C-2（明显的主要 KIE）发现了一个较小的值 1.2。在这些发现的基础上，提出了一种机械解释，其特征是亲电钯...